The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review protocol

Simple item page
dc.contributor.authorDabrow Woods, A.
dc.contributor.authorGiometti, R.
dc.contributor.authorWeeks, S.
dc.date.issued2014
dc.description.abstractReview question/objective - In adult intensive care unit patients experiencing alcohol withdrawal, does the use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy decrease delirium severity more effectively than benzodiazepine-based therapy alone? The objective of the systematic review is to examine the best available evidence of the clinical effectiveness of dexmedetomidine as an adjuvant to benzodiazepine-based therapy versus benzodiazepine-based therapy alone, in decreasing delirium severity associated with alcohol withdrawal in adult intensive care unit patients over the age of 18 years.
dc.description.statementofresponsibilityAnne Dabrow Woods, Renee Giometti, Susan Weeks
dc.identifier.citationThe JBI Database of Systematic Reviews and Implementation Reports, 2014; 12(1):74-89
dc.identifier.doi10.11124/jbisrir-2014-1285
dc.identifier.issn2202-4433
dc.identifier.issn2202-4433
dc.identifier.urihttp://hdl.handle.net/2440/91709
dc.language.isoen
dc.publisherJoanna Briggs Institute
dc.rightsCopyright status unknown
dc.source.urihttp://dx.doi.org/10.11124/jbisrir-2014-1285
dc.subjectalcohol withdrawal syndrome; benzodiazepine-based therapy; delirium; dexmedetomidine; intensive care unit
dc.titleThe use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review protocol
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Translational Health Science publications